52 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
investments, that, paired with our enhanced deal skillset and expanded team, are expected to add robust programs and diversity to our product pipeline … in FSGS; the timing of clinical and regulatory events of Ligand’s partners; the expansion and diversity of Ligand’s portfolio; and guidance regarding
425
EX-99.1
81bx p84p46iayejao09
21 Jun 22
Business combination disclosure
8:00am
8-K
EX-99.1
mmboxeg58fke71t iva
21 Jun 22
Regulation FD Disclosure
6:19am
425
EX-99.3
8ubrjq99 0kh55fstz
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.2
or2 fvg88dh3nou75uy5
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
lc9fp effr81lxzm6
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
sk8urg
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
8xsr1y7oxv d471jig4
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
3vyw1p55cl8vbj6 r0nb
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
DEFA14A
2i1 3jfg1
4 Jun 19
Additional proxy soliciting materials
5:07pm